Immuneering Corporation
IMRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $2 |
| % Growth | – | -100% | -84.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $1 |
| Gross Profit | $0 | $0 | $0 | $1 |
| % Margin | – | – | 50.1% | 44.6% |
| R&D Expenses | $48 | $42 | $36 | $27 |
| G&A Expenses | $16 | $17 | $16 | $8 |
| SG&A Expenses | $16 | $17 | $16 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $64 | $58 | $52 | $35 |
| Operating Income | -$64 | -$58 | -$52 | -$34 |
| % Margin | – | – | -16,325.8% | -1,629.2% |
| Other Income/Exp. Net | $3 | $5 | $1 | $0 |
| Pre-Tax Income | -$61 | -$53 | -$51 | -$34 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$61 | -$53 | -$51 | -$34 |
| % Margin | – | – | -15,937.3% | -1,612.3% |
| EPS | -2.04 | -1.88 | -1.87 | -1.27 |
| % Growth | -8.5% | -0.5% | -47.2% | – |
| EPS Diluted | -2.04 | -1.88 | -1.87 | -1.27 |
| Weighted Avg Shares Out | 30 | 28 | 26 | 26 |
| Weighted Avg Shares Out Dil | 30 | 28 | 26 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $3 | $4 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$64 | -$58 | -$51 | -$34 |
| % Margin | – | – | -16,238.4% | -1,621.5% |